At the end of the day, both Menon and Evans say that human trials and the FDA may initially lead to the disease Kevetrin will be focused on for treatment and approval, but having a drug that can be applied in different areas will be great in the long run.
Evans points out that is not unusual for cancer drugs to get initial approval to treat one area, such as lung cancer (or retinoblastoma;) and then get broader and broader approvals to treat other areas that the drug shows signs of combating. "We would ultimately try to get approval for a range of these indications," he said. "We have potential in a number of different areas and we will try to exploit these areas."
A shift of focus for a drug, initially targeted to treat one type of problem, but found to also treat another, is not unusual for the pharmaceutical industry. Well known examples include Viagra and Rogaine, both of which were initially targeted to treat diseases unrelated to the effects the drugs have now become famous for.
News 
Market Data 
Discover 
